<DOC>
	<DOC>NCT02710188</DOC>
	<brief_summary>The purpose of this study is to find a modified release oral tablet formulation for this drug, which will be safe and well tolerated.</brief_summary>
	<brief_title>Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation</brief_title>
	<detailed_description>The aim of the study is to develop a modified release oral tablet formulation that maintains plasma concentrations within the target therapeutic range, and is safe and tolerable.</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Healthy males &amp; females Aged 18 to 65 years Body mass index of 18.0 to 35.0 kg/m2 CYP2D6 (intermediate or extensive metabolizer) Subjects with a resting heart rate (HR) &gt;90 bpm, and/or systolic blood pressure (BP) &gt;150 mmHg, and/or diastolic BP &gt;90 mmHg Subjects with QT interval corrected for heart rate using Fridericia's formula (QTcF) &gt;450 ms (males) or &gt;470 ms (females) Personal or family history of long QT syndrome or sudden death Subjects who are CYP2D6 (poor or ultrarapid metabolizer)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>